



New Insights into GFAP Negative Astrocytes in
Calbindin D28k Immunoreactive Astrocytes
Jie Xu 1,2
1 Department of Cellular Physiology (in Biomedical Centre Munich—BMC), Ludwig-Maximilians-University
Munich, 82152 Planegg-Martinsried, Germany; xu@wickerklinik.de; Tel.: +49-6172-103101
2 Wicker Clinic, 61348 Bad Homburg, Germany
Received: 26 May 2018; Accepted: 31 July 2018; Published: 3 August 2018


Abstract: Glial fibrillary acidic protein (GFAP) is commonly used as a specific marker for the
identification of astrocytes. Nevertheless, it is known from the literature that astrocytes in situ
in contrast to cultured astrocytes may feature lower levels of GFAP. In order to characterize the
properties of GFAP in Calbindin D28k immunoreactive astrocytes, we use primary astrocyte cultures
from cells of new-born mice. A double fluorescence immunocytochemical analysis reveals that
GFAP in cultured Calbindin D28k astrocytes behaves differently depending on whether the medium
contains foetal bovine serum (FBS) or not. The novelty in our study is, however, that a high percentage
of Calbindin D28k cultured astrocytes in a medium with 10% FBS are GFAP negative. In addition,
the study shows that Calbindin D28k astrocytes have (i) a different morphology and (ii) a higher
concentration of Calbindin D28k in the nucleus than in the cytoplasm. The study provides new
evidence that in order to fully understand the characteristics of astrocytes, astrocytes which are
Calbindin D28k positive have to be investigated.
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1. Introduction
Astrocytes are the major glial cell of the CNS. It’s assumed in the literature that astrocytes contain
characteristic intermediate filaments, called glial filaments, which are mostly polymers of glial fibrillary
acidic protein (GFAP). Therefore, GFAP can be used for astrocyte identification [1]. Put differently,
the immunocytochemistry of GFAP is crucial for the identification of astrocytes [2]. Astrocytes are
morphologically subdivided into protoplasmic astrocytes with short, thick, branching protrusions in
the grey matter of the CNS and fibrous astrocytes with numerous, long and thin protrusions in the
white matter of the CNS. The morphological differences are due to the cell content of GFAP [3].
However, there is a controversy surrounding the fact that the marker GFAP serves to identify
astrocytes. Firstly, there is research arguing that the amount of GFAP in astrocytes can vary. Numerous
studies have demonstrated an increased amount of GFAP in reactive astrocytes in different types of
lesions or in cultured astrocytes [4–6]. Secondly, it has become clear that not all astrocytes in vivo
express GFAP, or only weakly so [6–10]. These studies have revealed a remarkable heterogeneity
among astrocytes, the elucidation of which is ongoing [11,12]. There is even evidence in the literature
that subpopulations of astrocytes are GFAP-negative [13–15]. The findings question whether the
expression of GFAP is at all comparable in different astrocytes.
In the present study, a double fluorescence immunocytochemical analysis was used to examine
the co-localization of Calbindin D28k and astrocytic marker GFAP in the cultured astrocytes from
mice. We have made a novel observation about the GFAP modification in Calbindin D28k astrocytes
under various conditions. In a medium with 10% FBS, the amount of GFAP gradually decreases,
while in a medium without FBS, the amount of GFAP stays almost the same. These results could
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be support for the studying the characteristics of GFAP and a functional analysis of Calbindin D28k
immunoreactive astrocytes.
2. Materials and Methods
2.1. Preparation of Cell Cultures
Cortical astrocytes were prepared from new-born mice (1 to 3-day-old mice were used).
For organ harvesting, wild-type mice are used (C57BL/6, Calbtm 1–15.B, 2.B, 1.I, Frox 26.B and
GtRosa 26 tm1.I breeding mice, own breed from animal house of the physiological institute at the
Ludwig-Maximilians-University in Munich).
Two tissue flasks were coated with 10 µg/mL of poly-L-Lysine overnight at 4 ◦C, rinsed with
water, and dried for 15 min.
Hemispheres from the whole forebrain of mice were separated. Meninges and capillary vessels
were removed. The tissues were cut into small pieces and incubated for 30 min. at 37 ◦C in a
Hanks-balanced saline solution (HBSS) in which 2 mL contain 200 µL, 0.25% trypsin, and 20 µL,
1 mg/mL DNAse. The medium containing 10% foetal bovine serum (FBS) was then added to the
dissociation reaction. It was removed once the cortex tissue pieces had sunk to the bottom of the tube,
and replaced with a new medium. The cortex tissue pieces were mechanically dissociated using a
10 mL plastic pipette and subsequently with a flamed glass Pasteur pipette. In order to remove the
fibroblasts, the cells suspension was pre-adhered in an uncoated 10 cm cell culture vessel for 30 min.
at 37 ◦C. The supernatant was removed and split into two poly-L-lysine coated flasks. The cells were
cultured in the medium containing 10% FBS for 4 days and the medium was changed the following day.
On day 4, the cells were passaged for the first time. The cells were incubated with 1 mL of 0.25%
trypsin-EDTA in the cell incubator for 5 min. After the trypsin neutralization with a 20 mL medium
containing 10% FBS, the cells were centrifuged for 5 min. at 1000× g (no brake). The supernatant was
removed and the cells resuspended in 1 mL of medium containing 10% FBS. The number of cells was
determined using a hemocytometer. The cells (20,000 cells/50 µL) were plated with poly-L-Lysine
coated coverlids for histochemical staining. They were cultured for 9 days in a medium which either
contains or did not contain 10% FBS. The medium was changed the following day in order to remove
the FBS.
2.2. Immunocytochemistry
Astrocytes cultured on coverlids were fixed with 4% PFA (Paraformaldehyde) for approx. 20 min.
and permeabilized with a permeabilization buffer (PBS-CMF, 10% BSA and 0.1% Triton), which contains
0.1% Triton X-100 for 20 min. at room temperature. Non-specific binding was blocked by incubation
with a block buffer with 10% BSA (Bovine Serum Albumin) for 20 min. at room temperature. The cells
were incubated with primary antibodies in an antibody dilution buffer with 1% BSA and 0.1% Triton
X-100 overnight at 4 ◦C. The following day the cells were washed with PBS and incubated with
Alexa Fluor-conjugated secondary antibodies (1:2.000) and DAPI for nuclear staining in antibody
dilution buffer with 1% BSA and 0.1% Triton X-100 at room temperature for 1 h, washed with PBS and
mounted on glass slides using a mounting medium (Mowiol). Appropriate primary and secondary
antibodies were used in double labeling. All secondary antibodies were tested for cross-reactivity
and nonspecific reactivity. The primary antibodies used here as follows: anti-GFAP (1:1000; ab53554,
Abcam, Cambridge, UK), anti-Calbindin D28k (1:500, SWANT), anti-S-100 (1:100, ab4066, Abcam),
anti-ß-Tubulin III (1:1000, ab7751, Abcam); and the secondary antibodies are as follows: Alexa Flour
488 Donkey Anti-Rabbit, Alexa Flour 594 Donkey Anti-Goat, and Alexa Flour 594 Goat Anti-Mouse
(Invitrogen, Carlsbad, CA, USA). Images were captured using a laser scanning confocal microscope
(Zeiss LSM 710, Carl Zeiss GmbH, Germany) or Epifluorescence microscopy Zeiss S100.
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2.3. Counts
The number of Calbindin D28k positive glial cells on every coverlid was counted. The percentage
of Calbindin D28k and GFAP positive glial cells was calculated by dividing the number of positive
cells by the total number of Calbindin D28k glial cells per coverlid. The total number of cells (or rather
cell nuclei) on every coverlid was also counted with DAPI. The percentage of Calbindin D28k positive
glial cells was calculated by dividing the number of positive cells by the total number of cells (or rather
cell nuclei) per coverlid. Every counting was repeated three times.
A t-test for a two-sided distribution and unpaired data is carried out for statistic evaluation.
Differences are considered significant from a p-value of <0.05.
3. Results
We performed a time course study of the expression of GFAP in Calbindin D28k positive glial
cells. Just one day after the passage, the Calbindin D28k positive glial cells are visible.
In a medium which contains FBS, the majority of Calbindin D28k glial cells are stained positive
for GFAP at day 1, while after 9 days only a small percentage of Calbindin D28k glial cells are stained
positive for GFAP (Figures 1–3). According to our figure, it seems that Calbindin D28k was localized
mostly in the nucleus and GFAP was localized in the cellular processes. Thus, due to their expression
location, it does not show an overlapping colour response.
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Figure 1. Cultures in a serum-containing medium, 1 day after passage: Immunofluorescence with 
anti-GFAP (glial fibrillary acidic protein) (red, secondary antibody: donkey anti-goat IgG Alexa 
Fluor 594), and with anti-Calbindin D28k (polyclonal antibody from the company SWANT) (green, 
secondary antibody: donkey anti-rabbit IgG Alexa Fluor 488); Nuclear staining with DAPI 
(4′,6-diamidino-2-phenylindole dihydrochloride) (blue). Confocal microscopy. Left: zoom = 1, 
numerous GFAP-positive astrocytes (long arrows), in between 2 Calbindin D28k positive and 
GFAP-negative astrocytes (short arrows). Right: zoom = 4, higher magnification of the 2 Calbindin 
D28k positive astrocytes (short arrows). 
  
Figure 1. Cultures in a serum-containing medium, 1 day after passage: Immunofluorescence
with anti-GFAP (glial fibrillary acidic protein) (red, secondary antibody: donkey anti-goat IgG
Alexa Fluor 594), and with anti-Calbindin D28k (polyclonal antibody from the company SWANT)
(green, secondary antibody: donkey anti-rabbit IgG Alexa Fluor 488); Nuclear staining with DAPI
(4′,6-diamidino-2-phenylindole dihydrochloride) (blue). Confocal microscopy. Left: zoom = 1,
numerous GFAP-positive astrocytes (long arrows), in between 2 Calbindin D28k positive and
GFAP-negative astrocytes (short arrows). Right: zoom = 4, higher magnification of the 2 Calbindin
D28k positive astrocytes (short arrows).
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The number of Calbindin D28k positive glial cells from day 1 to day 9 in the medium with 10% 
FBS increased from 23 to −76 to −143 to −136 and finally to 181. The percentage of Calbindin D28k 
positive glial cells from day 1 to day 9 in the medium with 10% FBS increased from 1.85 × 10−3 to 
−3.35 × 10−3 to −3.78 × 10−3 to −3.47 × 10−3 to −4.28 × 10−3 (Figure 4). But the percentage of GFAP positive 
Figure 2. Cultures in a serum-containing medium, 5 days after passage: Immunofluorescence
with anti-GFAP (glial fibrillary acidic protein) (red, secondary antibody: donkey anti-goat IgG
Alexa Fluor 594), and with anti-Calbindin D28k (polyclonal antibody from the company SWANT)
(green, secondary antibody: onkey anti-rabbit IgG Alexa Fluor 488); Nuclear staining with DAPI
(4′,6-diamidino-2-phenylindole dihydrochloride) (blue). Confocal microscopy. Zoom = 4, numerous
GFAP-positive and Calbindin D28k n gative strocytes (long arrows), in between 2 Calbindin D28k
positive and GFAP-positive astrocytes (short arrows).
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Figure 3. Cultures in a serum-containing medium, 9 days after passage: Immunofluorescence
with anti-GFAP (glial fibrillary acidic protein) (red, secondary antibody: donkey anti-goat IgG
Alexa Fluor 594), and with anti-Calbindin D28k (polyclonal antibody from the company SWANT)
(green, secondary antibody: nkey anti-rabbit IgG Alexa Fluor 488); Nuclear staini g with DAPI
(4′,6-diamidino-2-phenylindole dihydrochloride) (blue). Confocal microscopy. Zoom = 4, numerous
GFAP-positive and Calbindin D28k negative strocytes (long arrows), in between 1 Calbindin D28k
positive and GFAP-negative astrocyte (short arrows).
The number of Calbindin D28k positive glial cells from day 1 to day 9 in the medium with 10%
FBS increased from 23 to −76 to −143 to −136 and finally to 181. The percentage of Calbindin D28k
positive glial cells from day 1 to day 9 in the medium with 10% FBS increased from 1.85 × 10−3 to
−3.35× 10−3 to−3.78× 10−3 to−3.47× 10−3 to−4.28× 10−3 (Figure 4). But the percentage of GFAP
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positive cells from day 1 to day 9 in the medium with 10% FBS gradually decreased from 64.69% to
−36.54% to−32.07% to−23.38% and finally to−17.47% of the total number of Calbindin D28k positive
glial cells. This result can be confirmed via a computer-based calculation (Curve expert 1.4). At the
outset of the investigation, 92% of the Calbindin D28k positive glial cells are GFAP positive (Figures 5
and 6). All Calbindin D28k positive glial cells are S100ß positive, but negative with fibronectin, CD31,
aquaporin 4, and antibodies against oligodendrocyte (data not shown). In other words, all Calbindin
D28k positive glial cells are astrocytes.
The number of Calbindin D28k positive glial cells from day 1 to day 9 in the medium without FBS
increased from 21 to −25 to −40 to −41 and finally to 82. The percentage of Calbindin D28k positive
glial cells from day 1 to day 9 in the medium without FBS firstly increased from 3.89 × 10−3 to −4.87
× 10−3 to −6.47 × 10−3, then decreased to −4.74 × 10−3 to −4.25 × 10−3 (Figure 4). However, in the
medium without FBS, the percentage of GFAP positive cells from day 1 to day 9 stayed almost the
same: from 63.81% to −52.67% to −53.40% to −62.33% and finally to −55.20% of the total number of
Calbindin D28k positive glial cells. As already explained in the methods, approximately 24 h after
the passage, the medium with 10% FBS is replaced by a medium without FBS. Interestingly, in the
absence of FBS in the culture medium, there are noticeably higher, but nearly unchanged levels of
GFAP in Calbindin D28k positive glial cells. No further reduction of the percentage of GFAP positive
glial cells can be seen (Figure 5). In addition, the Calbindin D28k occurs in astrocytes in the nucleus
with a much higher concentration than in the cytoplasm not only in the medium with 10% FBS but
also in the medium without FBS.
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in the medium with 10% FBS or in the medium without FBS. p = 0.0187, significant.
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Figure 6. The computer-based calculation showed at the outset of the investigation 92% that Calbindin
D28k positive glial cells are also GFAP-positive. The blue circle: the percentage of GFAP positive cells
from day 1 to day 9 in the medium with 10% FBS gradually decreased from 64.69% to −36.54% to
−32.07% to −23.38% and finally to −17.47% of the total number of Calbindin D28k positive glial cells.
The red line: adjustment of the data with Curve expert 1.4.
It was also observed that in the absence of FBS a differentiation was taking place. The increase
in Calbindin D28k positive astrocytes was accompanied by morphological changes. They develop
protrusions, their polygonal form changed into a star-shaped form (Figures 7–14).
It was also observed that several neural extensions of Calbindin D28k expressing neurons are in
close contact with Calbindin D28k astrocytes. This shows a tight relationship between Calbindin D28k
astrocytes and nerve cells which is advantageous for neurons (Figures 15 and 16).
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Figure 7. Cultures in a serum-free medium, 5 days (6 days after the passage): Immunofluorescence
with anti-GFAP (glial fibrillary acidic protein) (red, secondary antibody: donkey anti-goat IgG
Alexa Fluor 594), and with anti-Calbindin D28k (polyclonal antibody from the company SWANT)
(green, secondary antibody: donkey anti-rabbit IgG Alexa Fluor 488); Nuclear staining with DAPI
(4′,6-diamidino-2-phenylindole dihydrochloride) (blue). Confocal microscopy. Zoom = 4, 2 Calbindin
D28k positive and GFAP-positive astrocytes (long arrows) with processes (short arrows).
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Figure 10. Cultures in a serum-free medium, 5 days (6 days after the passage): Immunofluorescence
with anti-GFAP (glial fibrillary acidic protein) (red, secondary antibody: donkey anti-goat IgG
Alexa Fluor 594), and with anti-Calbindin D28k (polyclonal antibody from the company SWANT)
(green, secondary antibody: donkey anti-rabbit IgG Alexa Fluor 488). Epifluorescence microscopy.
Three Calbindin D28k positive and GFAP-positive astrocytes (long arrows) with processes.
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Figure 13. Cultures in a serum-free medium, 3 days (4 days after the passage): Immunofluorescence
with anti-GFAP (glial fibrillary acidic protein) (red, secondary antibody: donkey anti-goat IgG
Alexa Fluor 594), and with anti-Calbindin D28k (polyclonal antibody from the company SWANT)
(green, secondary antibody: donkey anti-rabbit IgG Alexa Fluor 488). Epifluorescence microscopy.
One Calbindin D28k positive and GFAP-positive astrocyte (long arrows), besides, 1 Calbindin D28k
positive and GFAP-weak-positive astrocyte (short arrows).
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Figure 14. Cultures in a serum-free medium, 1 day (2 days after the passage): Immunofluorescence with
anti-GFAP (glial fibrillary acidic protein) (red, secondary antibody: donkey anti-goat IgG Alexa Fluor
594), and with anti-Calbindin D28k (polyclonal antibody from the company SWANT) (green, secondary
antibody: donkey anti-rabbit IgG Alexa Fluor 488). Epifluorescence microscopy. One Calbindin D28k
positive and GFAP-positive astrocyte (long arrows).
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igu e 15. Cultures in a serum-co taining medium, 1 day after the passage: Immunofluorescence
with anti-GFAP (glial fibrillary acidic protein) (red, secondary antibody: donkey anti-goat IgG
Alexa Fluor 594), and w th anti-Calbindin D28k (polyclonal antibody from the company SWANT)
(gree , secondary antibody: donkey anti-rabbit IgG Alexa Fluor 488); Nuclear staining with
DAPI (4′,6-diamidino-2-phenylindole dihydrochloride) (blue). Confocal microscopy. Zoom = 4.
Left: a Calbindin D28k positive and GFAP positive astrocyte (short arrows). Besides: a Calbindin D28k
positive and Calbindin D28k expressing neuron (triangle) with extensions (long arrows).
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Figure 16. Cultures in a serum-containing medium, 5 days after the passage: Immunofluorescence
with anti-ß-tubulin-III (red, secondary antibody: goat anti-mouse IgG Alexa Fluor 555), and with
anti-Calbindin D28k (polyclonal antibody from the company SWANT) (green, secondary antibody:
donkey anti-rabbit IgG Alexa Fluor 488); Nuclear staining with DAPI (4′,6-diamidino-2-phenylindole
dihydrochloride) (blue). Confocal microscopy. Left: zoom = 1, numerous ß-tubulin-III-positive neurons
(long arrows), on the right 1 Calbindin D28k positive and tubulin-III-positive neuron (short arrows).
Right: zoom = 4, higher magnification of the Calbindin D28k positive and tubulin-III-positive neuron
(short arrows) with extensions (long arrows). Above some Calbindin D28k positive astrocytes.
4. Discussion
In this study, we focus on cultured Calbindin D28k immunoreactive astrocytes which are GFAP
negative, not positive as standardly assumed in the literature [16,17]. The observations allow new
insights into the behaviour of GFAP in cultured astrocytes under different conditions. The study shows
that only the investigation of GFAP negative astrocytes leads to the complete understanding of the
role of GFAP as a marker for astrocytes.
As already mentioned in the introduction, GFAP is standardly used as a marker for astrocytes,
especially for cultured astrocytes [18–20]. This is based on results such as those reported in Du et al. [19],
who found that in a primary culture of astrocytes taken from new-born mice 90% are GFAP positive.
The present study doubts that GFAP is a reliable marker for astrocytes. It shows that a substantial
amount of cultured Calbindin D28k astrocytes are GFAP negative. The percentage of GFAP negative
cells from day 1 to day 9 in the medium with 10% FBS gradually increased from 35.31% to −63.46% to
−67.3% to −76.62% and finally to −82.53% of the total number of Calbindin D28k immunoreactive
astrocytes. Therefore, analyses using GFAP as a marker may lead to wrong results.
Secondly, the results of the present study also provide further evidence against the assumption
that GFAP negative astrocytes are only a subpopulation within a culture of astrocytes which are
generally GFAP positive. We observe that the expression of GFAP in Calbindin D28k immunoreactive
astrocytes depends on conditions in the astrocytes’ environment. We find that the presence vs. absence
of FBS in the medium plays an important role. In a medium, which contains 10% FBS, GFAP gets
downregulated after passage. This is in contrast to a medium without FBS, where the amount of GFAP
stays almost the same. In other words, astrocytes are argued to be heterogeneous [21]. Walz and
Lang [13] observed subpopulations without GFAP [10]. In the present study, there is, however,
no evidence for such a heterogeneity of astrocytes. Calbindin D28k immunoreactive astrocytes at
day 9 in a medium with 10% FBS are generally GFAP negative because it does not get expressed.
With the computer-based calculation, all Calbindin D28k astrocytes are presumably GFAP positive at
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the beginning of a passage in a medium with 10% FBS. This study shows that the expression of GFAP
in Calbindin D28k immunoreactive astrocytes is dynamic.
However, the percentage of GFAP positive cells from day 1 to day 9 in the medium without serum
remains at approximately the same level as that of the total number of Calbindin D28k astrocytes,
although GFAP is degraded. It can be assumed that all newly formed Calbindin D28k immunoreactive
astrocytes are daughter cells of the original cells and in this way the proportion (GFAP) of approx.
60% of Calbindin D28k astrocytes can be maintained. If the spontaneous new formation of Calbindin
D28k immunoreactive astrocytes were to occur, the percentage of GFAP positive cells of Calbindin
D28k astrocytes would have to change.
Further, the study at hand shows that the presence vs. absence of serum has an impact on the
amount of GFAP expressed in astrocytes containing Calbindin D28k. Interestingly, the lack of serum
leads to important changes. Firstly, the amount of GFAP increases significantly, that is, the astrocytes
become reactive. This result is unexpected because, in the literature, the withdrawal of serum and
the starvation of serum is reported to cause a decrease in GFAP mRNA levels. Only astrocytes in a
serum with rich growth factors are found to be reactive and expressing higher levels of GFAP [22].
Secondly, the lack of serum in the medium leads to a change in the morphology of the Calbindin
D28k immunoreactive astrocytes, more specifically, from a polygonal occurrence to a gigantic star-like
appearance. Kettenmann and Verkhratsky [20] pointed out that, an archetypal morphological feature
of astrocytes is their expression of intermediate filaments, which form the cytoskeleton. The main
type of astroglial intermediate filament protein is GFAP. Astrocytes can considerably increase their
volume, particularly under pathological conditions. The stretch-activated Ca2+-permeable channels
could link the regulation of cell volume to intracellular Ca2+ signalling [23]. Calbindin D28k belongs to
the large family of EF-hand calcium-binding proteins. Structurally these proteins are characterized by
the presence of a variable number of evolutionary well-conserved helix-loop-helix motives, which bind
Ca2+ ions with high affinity. Functionally, they fall into two groups: by interaction with target proteins,
calcium sensors translate calcium concentrations into signalling cascades, whereas calcium buffers are
thought to modify the spatiotemporal aspects of calcium transients [24]. In view of the documents
described above, Calbindin D28k immunoreactive astrocytes with more GFAP may fulfil several
functions and be able to adapt to the environment without FBS.
Thirdly, cultured Calbindin D28k astrocytes are special with respect to the intensity of their
Calbindin D28k immunoreactivity. While it is less intense in the cytoplasm it is more intense in the
nucleus. It is well known that the synthesis of proteins takes place in the cytoplasm. Christie et al. [25]
invoked that the translation of proteins can only take place in the cytoplasm. However, they came
to the conclusion that many proteins are only able to fulfil their function then, if they are in the
nucleus. The active uptake of proteins into the nucleus is a fast, specific and evolutionary conserved
process [26,27]. The spatial separation of transcription and translation provides eukaryotes with
powerful mechanisms for controlling gene expression [28]. Regulatory proteins, such as RNA binding
proteins, play an important role throughout gene expression from transcription to translation [29,30].
In our study, we observe whether the presence vs. absence of FBS has an impact on the intense of
Calbindin D28k in the nucleus. We arrive at the conclusion that the more intense Calbindin D28k in the
nucleus does not change. It is as high in a medium with 10% FBS as in one without FBS. This finding
could be linked to the fact that Calbindin D28K in the nucleus is responsible for many cell functions
and therefore does not get downregulated. Calbindin D28K in the nucleus possibly regulates the gene
expression in the cell nucleus and thus influences all cell functions. To investigate the underlying
mechanisms leading to and the consequences of the more intense Calbindin D28k in the nucleus would
be important questions for future research on Calbindin D28k astrocytes.
In this study, we find that Calbindin D28k astrocytes influence neurons in their neighbourhood.
Several neuronal processes next to Calbindin D28k astrocytes seem to develop thicker and stronger
than others without contact with Calbindin D28k astrocytes. This raises questions about signalling
processes between neurons and astrocytes for the benefit of neurons. Although we cannot answer the
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question how neurons and astrocytes communicate with each other, we suspect that Calbindin D28k
astrocytes are able to produce a still unknown factor, which has positive effects on the development
of neurons close to them. It has already been reported in the literature that astrocytes are able to
secrete a whole series of neurotrophic proteins, e.g., NGF, BDNF, NT-3, bFGF CNTF, as well as
neuropeptides, somatostatin and substance P, which can further promote the survival of neurons and
regrowth [12,16,31,32].
Another important result of the present study is the decrease in Calbindin D28k immunoreactive
astrocytes in the medium without serum following the observed increase. The assumption is again
that the Calbindin D28k astrocytes produce an unknown factor that improves the condition of the cell.
It can further promote the survival and regrowth of neurons. This improved condition leads to the
observed decrease in Calbindin D28k astrocytes. Under the improved conditions, the cells appear to
require less Calbindin D28k and therefore to experiment less.
5. Conclusions
In this study, we do research the GFAP negative astrocytes in cultured Calbindin D28k
immunoreactive astrocytes. The observations make it possible to reveal an aspect of GFAP in cultured
astrocytes under various conditions which until now has been underappreciated. Our findings
provided clear evidence of the biological characteristics of Calbindin D28k astrocytes. However,
it needs to be stated that there is much more research to be done. One possible research question
would be to investigate the elevated concentration of Calbindin D28k in the nucleus of Calbindin
D28k astrocytes. The focus could be on the factors which may influence the growth of the
surrounding neurons.
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